|
|
| Biotechnologies Et Génétique > Etude de marché sectorielle |
|
|
|
|
€ 1 200,00 |
Editeur
: |
ZZZ - Biovista |
Langue
: |
Anglais |
Date de publication : |
Juillet 2001 |
Taille du document : |
N/A |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Pharmacogenomics
160 pages | Décembre 2000 |
The Human Genome Project and numerous corporate and academic human gene sequencing efforts have revealed, among others, that genes exist in the population in numerous mutated forms, some of which |
1 400,00 €
|
| |
| |
The Genomics Outlook To 2005: Transforming pharmaceutical and diagnostic markets
150 pages | Janvier 2002 |
Genomics is quietly transforming the pharmaceutical industry.
Companies are moving from medicinal chemistry based drug discovery and development, to using information provided by genomics.
V |
953,48 €
|
| |
| |
05-001: Improving Sales Rep Performance: A Global Analysis
219 pages | Janvier 2005 |
This report is designed to offer insights on how sales executives can align their sales force organization, recruitment and training in a way that reflects the needs and expectations of scientific cus |
1 520,00 €
|
| |
| |
Bioinformatics
150 pages | Décembre 2000 |
Automation has assaulted several levels of biological research generating vast amounts of data.
Great leaps in DNA sequencing technology and automation led to a dramatic increase in sequence th |
1 400,00 €
|
| |
| |
03-054: Immunohistochemistry Market Benchmarking Survey
90 pages | Octobre 2003 |
This report provides an overview of the most commonly used methods and products for tissue/sample preparation and antigen detection to help suppliers understand researchers’ experiences, preferences a |
680,00 €
|
| |
| |
Combinatorics
150 pages | Décembre 2000 |
Identified by The Economist (*) as the industry to watch for 1997 in the chemicals sector, Combinatorics (also known as combinatorial chemistry) is an emerging platform technology that uses test t |
1 400,00 €
|
| |
| |
DNA Sequencing and PCR Markets
252 pages | Novembre 2004 |
The focus of this report is to describe the specific segment of the life sciences market called DNA sequencing.
This analysis includes all of the generally accepted DNA-oriented analytical activiti |
2 800,00 €
|
| |
| |
03-019: The Market for Microbial Genotyping Products: Research and Testing Applications
183 pages | Juin 2003 |
The report identifies the kits, reagents and instrumentation that are most commonly used for microbial identification and analysis in both the research and testing arenas |
800,00 €
|
| |
| |
Biogenerics: Challenges and Promise
154 pages | Janvier 2005 |
Biogenerics: Challenges and Promise takes an insightful look at the burgeoning biogenerics industry and helps to clarify the complicated regulations that currently govern biogeneric development in bot |
799,20 €
|
| |
| |
Carbohydrate Therapeutics IRCD
pages | Juillet 2001 |
Carbohydrates are the only class of biological molecule (there are four main classes: nucleic acids, proteins, lipids, and carbohydrates - commonly known as sugars), that can be found in direct associ |
1 200,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
|
|
The Human Genome Project and numerous corporate and academic human gene sequencing
efforts have revealed, among others, that genes exist in the population in numerous
mutated forms, some of which are disease-causing, some of which are not. This
variability is also being linked to variable drug responses, where the same drug
will have a different effect on patients with the same disease, because the patients'
genes that are affected are not identical. As a corollary, there is a growing
need for the rapid, accurate, and cheap detection of gene mutations both at the
individual and also at the population levels. This problem can thus be described
in terms of two components: Firstly, there is the issue of defining gene mutations
and variability at the individual level that affect disease progression but also
response to particular drugs. Drug response variability and its use for drug therapy
optimization is the essence of so-called pharmacogenomics. Secondly, phamracogenomic
information must be converted not just to more tailored therapeutics, but also
to high quality genetic diagnostics, if the value of genomic data is to be realized
to its full potential. This inevitable marriage of genomics and pharmacogenomics
with diagnostics is driving a great deal of corporate excitement in biotechnology
today.
|
|
I) KNOWLEDGE BLOCK 1: TECHNOLOGY SUMMARY
A) Background
B) Evolution of the Field
C) Approved Drugs
D) Development Issues
E) Clinical Efforts
F) Future Developments
G) Technology Examples
H) Orphan Nuclear Receptor Signal Transduction
I) The JAK/STAT Machinery
J) The Notch Signal Transduction Machinery
KNOWLEDGE BLOCK 2: BUSINESS DEVELOPMENT
A) Platform Biotechnologies
B) Current Conditions
C) Market Size Estimates
D) Synopsis of Notable Events in 1997-1999 (YTD)
E) Descriptions of Corporate Activities in 1997-1999 (YTD)
F) Discussion of Corporate Activities in 1997-1999 (YTD)
KNOWLEDGE BLOCK 3: COMPANY DATABASE
A) Methodology
B) Concise Company Listing
|
|
|
PPLSEN
|
|
|
|
|
